Brinavess (Atrial Fibrillation) - Analysis and Forecasts to 2022

GlobalData, May 2012, Pages: 37

Brinavess (Atrial Fibrillation) – Analysis and Forecasts to 2022

Summary

GlobalData’s pharmaceuticals report, “Brinavess (Atrial Fibrillation) – Analysis and Forecasts to 2022” provides Brinavess global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2022). The report also includes information on Atrial Fibrillation market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US and EU5 (six major markets)
- Analysis and review of Brinavess including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Brinavess including efficacy, safety, pricing, competition and other details which influence its sales potential
- Global sales forecast for 2010-2022 for Brinavess

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets

Keywords

Brinavess, vernakalant, normal heart rhythm, atrial fibrillation, cardioversion, solution for intravenous infusion

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Atrial Fibrillation Market
2.2 Epidemiology
2.3 Etiology and Risk Factors
2.3.1 Symptoms associated with AF
2.4 GlobalData Analysis and Forecasts Report Guidance
3 Atrial Fibrillation: Market Characterization
3.1 Atrial Fibrillation Market
3.2 Atrial Fibrillation Market Forecasts and CAGR
3.3 Drivers of Atrial Fibrillation Market
3.3.1 High Unmet need
3.3.2 Strong Pipeline
3.3.3 Increase in prevalence and ageing populations
3.3.4 Organisation of Awareness Campaigns
3.4 Barriers in Atrial Fibrillation Market
3.4.1 Limitations in established therapies
3.4.2 High cost of emerging therapies
4 Classification in Atrial Fibrillation: Introduction
4.1 AF Classification
4.1.1 Pathophysiology of AF
4.1.2 Diagnosis in Atrial Fibrillation
4.1.3 Impact of Atrial Fibrillation
5 Treatment Options and Management in Atrial Fibrillation
5.1 Rate control and Rhythm control
5.2 Rate Control Versus Rhythm Control
6 Brinavess
6.1 Introduction
6.2 Mechanism of Action
6.3 Clinical Studies
6.4 Approval Status of Brinavess
6.5 Factors Affecting Sales of Brinavess
6.5.1 Unique Drug
6.5.2 Ventricular arrhythmias
6.5.3 Oral form of vernakalant
6.6 Drug Evaluation
6.6.1 Drug Risk Benefit Score
6.6.2 Intensity of Competition
6.7 Sales Forecasts
6.7.1 Target Patient Pool of Brinavess
6.7.2 Dosing
6.7.3 Market Penetration
6.7.4 Annual Cost of Therapy
6.7.5 Sales Projections of Brinavess
7 Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Number of Patients Approved to Take the Drug
7.3.5 Net Penetration of Drug
7.3.6 Net Annual Dosing
7.3.7 Annual Cost of Therapy
7.4 Drug Sales Estimates Model
7.5 Contact Us
7.6 Disclaimer
7.7 Sources

1.1 List of Tables
Table 1: Epidemiology of Atrial Fibrillation (2011)
Table 2: Increase in the Risk of AF in The Presence of Risk Factors
Table 3: Stratification of All Risk Factors For Atrial Fibrillation
Table 4: Atrial Fibrillation Classification
Table 5: Treatment Guidelines For the Management of Atrial Fibrillation
Table 6: Brinavess, (EU) Approval Status
Table 7: Drug Risk Benefit Score of Brinavess
Table 8: Brinavess, Atrial Fibrilation, Global, Cost of Therapy, 2011
Table 9: Brinavess, Atrial Fibrillation, Global, Sales Forecasts ($m), 2010–2022
Table 10: Brinavess, Atrial Fibrillation, The US, Sales Forecasts ($m), 2015-2022
Table 11: Brinavess, Atrial Fibrillation, The UK, Sales Forecasts ($m), 2010–2022
Table 12: Brinavess, Atrial Fibrillation, France, Sales Forecasts ($m), 2010–2022
Table 13: Brinavess, Atrial Fibrillation, Germany, Sales Forecasts ($m), 2010–2022
Table 14: Brinavess, Atrial Fibrillation, Italy, Sales Forecasts ($m), 2010–2022
Table 15: Brinavess, Atrial Fibrillation, Spain, Sales Forecasts ($m), 2010–2022

1.2 List of Figures
Figure 1: Atrial Fibrillation, Global, Market Size Forecasts ($bn), 2011–2022
Figure 2: Percentage Of Molecules (in Different Phases of Development) For Atrial Fibrillation
Figure 3: Increase of Prevalance Population in Atrial Fibrillation
Figure 4: Normal Heart Rhythm Vs Atrial Fibrillation
Figure 5: Broad classification of Patterns in Atrial Fibrillation
Figure 6: Disease States Associated with Atrial Fibrillation, By (%)
Figure 7: Therapeutic Goals in Patients with Atrial Fibrillation (AF)
Figure 8: Management of Newly Discovered Atrial Fibrillation (AF)
Figure 9: Drug Model Diagram of Brinavess
Figure 10: Brinavess, Atrial Fibrillation, Global, Sales Forecasts ($m), 2010–2022
Figure 11: Brinavess, Atrial Fibrillation, The US, Sales Forecasts ($m), 2015–2022
Figure 12: Brinavess, Atrial Fibrillation, The UK, Sales Forecasts ($m), 2010–2022
Figure 13: Brinavess, Atrial Fibrillation, France, Sales Forecasts ($m), 2010–2022
Figure 14: Brinavess, Atrial Fibrillation, Germany, Sales Forecasts ($m), 2010–2022
Figure 15: Brinavess, Atrial Fibrillation, Italy, Sales Forecasts ($m), 2010–2022
Figure 16: Brianvess, Atrial Fibrillation, Spain, Sales Forecasts ($m), 2010–2022
Figure 17: Percentage Distribution of Global Sales of Brinavess by Countries in (2022)
Figure 18: Patients Approved for the Drug

Customers who bought this item also bought

• Global Atrial Fibrillation Market 2010-2014
• Cardiac Rhythm Management (CRM) Devices - Global Strategic Business Report
• Analysis of the Anticoagulant Market
• Cardiac Defibrillators - Global Strategic Business Report
• Medical Nutrition - A Global Market Overview
• Catheter Ablation of Atrial Fibrillation
• European Market for Cardiac Ablation Devices 2009 (15 Countries)
• Diabetes Diagnostics - Global Strategic Business Report
• Disinfectants - Global Strategic Business Report
• Syringes (Disposable and Reusable) - Global Strategic Business Report